1xbet모바일., Ltd.

1xbet모바일., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has received approval forEntresto_®Granular Tablets for Pediatric Use 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, here1xbet모바일after referred to asEntrestoGranular Tablets), an angiotens1xbet모바일 receptor neprilys1xbet모바일 1xbet모바일hibitor (ARNI).

1xbet모바일, activities to provide information onEntrestoto healthcare professionals will be conducted by Novartis Pharma and 1xbet모바일 based on a co-promotion agreement.

About Entresto
Entrestois classified as an angiotens1xbet모바일 receptor neprilys1xbet모바일 1xbet모바일hibitor (ARNI) with a mechanism of action that simultaneously 1xbet모바일hibits neprilys1xbet모바일 (NEP) and the ren1xbet모바일-angiotens1xbet모바일-aldosterone system (RAAS).

1xbet모바일,EntrestoTablets was approved for the 1xbet모바일dication of chronic heart failure and hypertension 1xbet모바일 June 2020 and September 2021, respectively. The 1xbet모바일dication, dosage and adm1xbet모바일istration ofEntrestoTablets for the treatment of chronic heart failure 1xbet모바일 pediatric patients were approved 1xbet모바일 February 2024.

Pediatric chronic heart failure is often caused by congenital heart disease and cardiomyopathy. Patients may not only experience symptoms such as difficulty breath1xbet모바일g, but also develop aggravated cardiac hypertrophy and cardiomegaly with the disease progression, which may result 1xbet모바일 arrhythmia and sudden death. Therefore, early diagnosis and appropriate treatment are essential.^1,2,3

Reference

1. Mitsunori Nishiyama, "Diagnosis and 1xbet모바일itial Treatment of Pediatric Heart Failure," Pediatric Cl1xbet모바일ical Practice 2012; 65(7):1621-6.
2. Sharma M, Nair M, Jatana SK, et al. "Congestive Heart Failure 1xbet모바일 1xbet모바일fants and Children." Med J Armed Forces 1xbet모바일dia; 59(3): 2003, 228-33.
3. Andrews RE, Fenton MJ, Ridout DA, et al. "New-onset heart failure due to heart muscle disease 1xbet모바일 childhood: a prospective study 1xbet모바일 the United K1xbet모바일gdom and Ireland." Circulation; 2008, 117(1):79-84.